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Abstract
Clinical trials today are conducted in multiple countries to enhance patient recruitment and improve
eﬃciency of trials. However, the demographic and cultural diversity may contribute to variations in study
outcomes. Here we conducted post-hoc analyses for a placebo-controlled study with ziprasidone and
haloperidol for the treatment of acute mania to address the demographic, dosing, and outcome disparities
in India, Russia and the USA. We compared the baseline characteristics, outcomes and discontinuations in
patients and explored the relationship between the outcome measures across these countries. We found
substantial diﬀerences in baseline characteristics of subjects, administered dosage and disease severity in
India compared to the USA and Russia. Conversely, US subjects had a higher placebo response compared
to subjects in Russia and India. These results are probably due to demographic diﬀerences in patient
populations and psychiatric clinical practice across countries. While we oﬀer initial ideas to address the
disparities identiﬁed in this analysis, it is clear that further research to improve our understanding of
geographical diﬀerences is essential to ensure globally applicable results for clinical trials in psychiatry.
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Introduction
International trials are designed to be conducted con-
sistently in all countries. However, prescribing prac-
tices and cultural diﬀerences may aﬀect enrolment and
outcomes, which could have important implications
for drug development and the design of international
clinical trials. For instance, in mania, a ﬂexible-dose
risperidone trial conducted in India revealed that
most patients were given doses very close to the upper
limit, despite their low body mass index (BMI)
(Khanna et al. 2005), and a failed aripiprazole trial in-
dicated diﬀerential rater performance across countries
as potential reason for study failure (El Mallakh et al.
2010).
A recent randomized, placebo-controlled trial
assessing the eﬃcacy of ziprasidone in acute mania
revealed that ziprasidone and haloperidol were inde-
pendently superior to placebo (Vieta et al. 2010). The
original trial was a 12-wk, double-blind study in 438
patients with bipolar mania started with a 3-wk com-
parison of ziprasidone (80–160 mg/d) with placebo or
haloperidol (8–30 mg/d). This was followed by a 9-wk
extension phase during which subjects continued on
ziprasidone or haloperidol, and those originally on
placebo were switched (with the appropriate escala-
tion) to ziprasidone. Superior changes from baseline
in Mania Rating Scale (MRS) scores were observed
for ziprasidone and haloperidol compared to placebo
from day 2 to week 3 and eﬃcacy was maintained
throughout the 9-wk extension phase. Although halo-
peridol showed greater eﬃcacy than ziprasidone, the
latter showed a better tolerability proﬁle (Vieta et al.
2010). We were particularly interested in country
variations related to placebo response, dosing, and
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tolerability. We hypothesized that the baseline subject
characteristics, dosage of study drugs and placebo
response diﬀered between the countries. We also
queried whether there were any diﬀerences by country
for overall measured outcome variables or when
restricting analyses to severely aﬀected subjects.
Further post-hoc analysis of the results of this study
revealed some variation in outcomes and adverse
events (AEs) results between countries, namely India,
Russia, and the USA, which are the objective of this
report.
Methods
Subjects
Data from a 12-wk, double-blind, two-part study in
438 adults with acute bipolar mania and a MRS score
of>14 at screening (with scores ofo2 on at least four
items) were analysed. Subjects received ﬂexibly dosed
ziprasidone (80–160 mg/d), haloperidol (8–30 mg/d)
or placebo during the ﬁrst 3 wk. During the sub-
sequent 9-wk extension phase patients either con-
tinued with ziprasidone (40–160 mg/d) or haloperidol
(8–30 mg/d). Due to the study design, some of the
subjects were on ziprasidone for a maximum of 9 wk,
while others for a maximum of 12 wk. In order to
eliminate any confound, the post-hoc analyses were
restricted to the ﬁrst 3 wk of the trial for all reported
results. For this analysis, subjects with at least a 50%
decrease in MRS score from baseline to week 3 were
deﬁned as MRS responders.
Statistical analyses
Baseline comparisons
A stepwise discriminant function was used to deter-
mine the combination of baseline variables that could
distinguish between the three countries (USA, India,
Russia). The variables derived from patient history
included age of onset of illness, BMI, duration of ill-
ness, mixed vs. manic at baseline, number of prior
hospitalizations, number of prior psychotropic medi-
cations and psychotic status at baseline. Other vari-
ables based on psychiatric evaluations included
baseline scores for MRS, Clinical Global Impression –
Severity (CGI-S), Global Assessment of Functioning
(GAF), Positive and Negative Syndrome Scale
(PANSS) Negative, baseline PANSS Positive, baseline
PANSS Total, hallucinations [Schedule for Aﬀective
Disorders and Schizophrenia – Change (SADS-C),
item 42] and Clinical Global Impression – Improve-
ment (CGI-I).
Dosage and outcome variables
An analysis of variance (ANOVA) model was used to
compare the average baseline weight with main eﬀects
for each treatment group, country and an interaction
between treatment and country. The relationship
between the outcome variables and dose of each group
was examined using multiple regression models using
last dose as a predictor for each country and treatment
group separately.
Next, separate multiple regression models were
examined to determine if these outcome variables
could successfully predict a therapeutic improvement,
as measured by MRS change from baseline to end-
point [i.e. the last observation carried forward (LOCF)
for each country]. An ANOVA was used to compare
the average MRS change from baseline to LOCF end-
point with main eﬀects for treatment and country, and
an interaction between treatment and country, while
controlling for baseline MRS score. The eﬀects sizes
by country were calculated according to Cohen’s d,
deﬁned as placebo-corrected treatment eﬀect/root
mean square.
In order to account for variability in baseline severity
between the countries, additional logistic regression
analyses were conducted, where the MRS at baseline
waso30.
To determine if geography had any placebo eﬀect,
Fisher’s exact tests were then used to compare the
proportion of responders in the placebo group be-
tween countries. This analysis was extended to all
treatment groups using a logistic regression model to
compare the proportion of responders (MRS change
from baseline o50%) with main eﬀects for treatment
and country and to test for an interaction between
treatment and country.
Relationship between the outcome variables
In order to investigate if there was any consistent re-
lationship between the outcome variables, a multiple
regression model was used with main eﬀects for
country and treatment. Pairwise comparisons were
used to determine which countries and treatments
were diﬀerent. To assess the precision of clinical
evaluation, MRS score at visit was correlated with
CGI-S at the same visit, andMRS change from baseline
to visit was correlated with CGI-I at the same visit.
Discontinuations and AEs
Estimates of time until discontinuation were made
using Kaplan–Meier analysis and these curves were
compared using a log-rank test. Rate of discontinuation
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due to lack of eﬃcacy was measured by reported AEs
or lack of eﬃcacy, exacerbation of mania or worsening
of disease, and was compared across the countries
using x2 tests of equivalence. The average numbers of
AEs experienced per subject were compared using an
ANOVA model for main eﬀects of country and treat-
ment and interactions between country and treatment.
Results
Baseline subject characteristics across countries
A total of 437 subjects were available for analysis
(safety population). We report the discriminant func-
tion analysis, with data for only 401 subjects due to
missing data, for predictors related to subject charac-
teristics that included age, BMI, duration of illness,
proportion of manic vs. mixed episodes, proportion
of psychotic subjects, number of prior psychotropic
drugs and hospitalizations, and psychiatric diagnostic
scales including MRS, CGI-S, GAF, SADC item 42 for
hallucinations, PANSS Negative, PANSS Positive and
PANSS Total scores. With the exception of the number
of prior hospitalizations, all other predictors added
signiﬁcantly to the discrimination among the three
countries, with p<0.0001 in each case. The USA
had the youngest subject population while Russia had
the oldest. The mean BMI at baseline was highest for
patients from the USA and lowest for patients from
India.
US subjects had been diagnosed with their illness
for the longest period of time followed by Russia and
then India (Table 1). However, the proportion of psy-
chotic subjects at baseline was highest in India with
the USA having the lowest numbers. Similarly, the
proportion of subjects with manic (vs. mixed) symp-
toms was high in India (98%) and Russia (83%), while
in the USA (53%) subjects were evenly split. In con-
trast, the US group had a longer duration of illness, the
most prior psychotropic medications and the greatest
number of prior hospitalizations. The least number of
prior psychotropic medications and prior hospitaliza-
tions were observed in India (Table 1).
Illness severity was measured at baseline using
psychiatric diagnostic scales, which included MRS,
which was the primary measure of bipolar mania, and
CGI-S, GAF and PANSS Total scores, which were
secondary measures. Based on these data, it appears
Table 1. Descriptive statistics for the baseline characteristics of the three countries
India
(n=166)
Russia
(n=123)
USA
(n=112)
Subject baseline characteristicsa
Age (yr) 24.82 (8.08) 25.01 (9.55) 21.70 (9.04)
BMI 22.17 (3.66) 24.85 (5.02) 28.38 (5.25)
Duration of illness (yr) 9.61 (8.17) 13.29 (10.02) 17.74 (10.90)
Proportion manic (vs. mixed) 0.98 (0.15) 0.83 (0.38) 0.53 (0.50)
No. of prior hospitalizations 3.02 (1.64) 6.04 (8.67) 9.13 (14.19)
No. of prior psychotropic medications 2.96 (1.92) 3.59 (2.17) 4.46 (2.50)
Proportion psychotic 0.45 (0.50) 0.35 (0.48) 0.29 (0.46)
Psychiatric diagnostic scoresa
MRS 34.48 (7.03) 30.43 (7.63) 24.07 (5.45)
CGI-S 5.02 (0.75) 4.83 (0.78) 4.40 (0.65)
GAF 35.83 (11.34) 40.94 (11.04) 47.01 (8.72)
PANSS Negative 8.19 (2.46) 9.77 (3.67) 12.82 (4.09)
PANSS Positive 20.50 (6.18) 18.12 (5.39) 16.88 (4.05)
PANSS Total 56.34 (14.31) 57.52 (12.89) 63.27 (11.80)
Hallucinations (SADS-C, item 42) 0.42 (1.02) 0.37 (0.93) 0.71 (1.14)
BMI, Body mass index ; MRS, Mania Rating Scale ; CGI-S, Clinical Global
Impression – Severity ; GAF, Global Assessment of Functioning ; PANSS, Positive
and Negative Syndrome Scale ; SADS-C, Schedule for Aﬀective Disorders and
Schizophrenia – Change.
Values are mean (S.D.)
a p<0.0001 for all comparisons in the table, except for the number of prior
hospitalizations.
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that subjects in the USA had the least severe bipolar
manic symptoms. While the study inclusion criteria
required MRS scores of>14, the subjects in India had
the worst disease severity, as mean baseline MRS
scores were considerably higher (34.48) than in Russia
(30.43) or the USA (24.07). These ﬁndings were con-
ﬁrmed with additional diagnostics where Indian sub-
jects had the lowest GAF scores and US subjects the
highest. In contrast, the CGI-S and PANSS Positive
scores were highest in Indian subjects and lowest in
US subjects. The PANSS Negative scores and the
PANSS Total scores were highest in US and Indian
subjects. The CGI-S scores were approximately equal
for subjects in Russia and India. Finally, US subjects
reported stronger hallucinations (SADS-C, item 42)
while Russian subjects were the least aﬀected (Table
1). Overall, in this study US subjects had been diag-
nosed and treated for longer, while Indian subjects
had the highest disease severity.
Baseline weight of subjects and dosage analysis
As observed in the previous analyses, the baseline
BMI was remarkably diﬀerent between countries.
Speciﬁcally, it was expected that there would be a
signiﬁcant diﬀerence in the average baseline weight
across the countries (each was signiﬁcantly diﬀerent
from the other at p<0.001). As previously indicated,
subjects in the USA were the heaviest at baseline
and those in India were the lightest. Notably, there
was no interaction between treatment and country and
there was no diﬀerence in average weight within the
treatment groups (Table 2).
Given these diﬀerences in baseline weight, it could
be expected that the doses prescribed were pro-
portional to the baseline weights. However, the mean
doses of ziprasidone at week 3 varied by country, with
subjects in Russia receiving lower doses of ziprasidone
than subjects in India or the USA. Similarly, the mean
dose of haloperidol at week 3 was lower in Russia than
in India or the USA. There was a signiﬁcant diﬀerence
in the modal dose (regardless of adjustment factor)
between India and both USA and Russia. The modal
doses in India were signiﬁcantly higher than in both
USA and Russia. There was no signiﬁcant diﬀerence
between the adjusted modal dose in USA and Russia
(Table 2).
Outcome variables across countries
Due to the diﬀerences in the baseline disease severity
and dosage between countries, the next analyses
aimed to investigate the relationship between out-
come variables, baseline characteristics and dosage.
Multiple regression models were used to determine if
baseline characteristics could predict change in MRS
score from baseline to LOCF endpoint (for each
country separately). No baseline characteristic was
a signiﬁcant predictor using a criterion of p<0.01.
However, in the model for India, psychotic at baseline
was a borderline signiﬁcant predictor (p=0.03) ; in
the US model, PANSS Negative score was a borderline
predictor (p=0.04), but in the model for Russia no
variable was signiﬁcant at p<0.05.
With respect to therapeutic eﬀects measured by
country, within-group MRS change at week 3 was
signiﬁcantly higher in India (ziprasidone x12.35,
haloperidol x19.59, placebo x5.81) than in the USA
(ziprasidone x11.10, haloperidol x12.64, placebo
x8.37) and Russia (ziprasidone x7.97, haloperidol
x13.80, placebox3.72) (Fig. 1). For ziprasidone com-
pared to placebo, the eﬀect sizes for MRS change from
baseline to endpoint were 0.52 in India, 0.39 in Russia
and 0.26 in the USA and 0.40 regardless of country.
The eﬀect size for haloperidol vs. placebo was the
largest for Russia (1.21), then India (1.12), then USA
(0.44) and overall (0.92). The eﬀect size for MRS
Table 2. Baseline weight and dosage analysis by country
(intent-to-treat population) at week 3
India Russia USA
N
Ziprasidone 74 56 47
Haloperidol 69 55 46
Placebo 36 28 24
LS mean weight, kg (S.E.)
Ziprasidone 57.95 (1.11) 73.50 (1.78) 82.38 (2.52)
Haloperidol 56.89 (1.59) 73.88 (1.79) 82.36 (2.54)
Placebo 57.13 (1.15) 60.04 (2.51) 83.71 (3.56)
Mean dosage at week 3 (mg/d)
Ziprasidone 128.4 121.8 126.5
Haloperidol 20.7 15.2 15.3
Placebo – – –
Mean modal dose per kg (S.D.)
Ziprasidone 2.41 (0.72)ab 1.53 (0.51)a 1.58 (0.59)b
Haloperidol 0.39 (0.20)ab 0.24 (0.25)a 0.22 (0.13)b
Placebo – – –
Mean modal dose/BMI (S.D.)
Ziprasidone 6.36 (2.00)ab 4.36 (1.45)a 4.62 (1.66)b
Haloperidol 1.00 (0.49)b 0.69 (0.80) 0.61 (0.35)b
Placebo – – –
LS, least squares ; BMI, body mass index.
a p<0.001 India vs. Russia.
b p<0.001 India vs. USA.
1020 E. Vieta et al.
change from baseline to endpoint for haloperidol
vs. ziprasidone was 0.60 for India, 0.83 for Russia, 0.18
for the USA and 0.52 regardless of country.
Finally, there was virtually no relationship between
mean modal dose or last dose of active drug
and change in MRS score from baseline to LOCF end
point (Table 3), indicating that the observed higher
therapeutic eﬀect in India was not related to the higher
administered doses.
Sub-analysis restricted to severely ill at baseline
As the severity of illness diﬀered between subjects in
the three countries, we investigated if this diﬀerence
impacted the treatment outcome. In subjects who were
severely ill (MRS o30 at baseline), there was a sig-
niﬁcant diﬀerence in change from baseline to LOCF
endpoint in MRS score when controlling for baseline
MRS score, treatment, country and treatmentr
country. There was a signiﬁcant diﬀerence between
ziprasidone and placebo in both India (p=0.001) and
the USA (p=0.007), but there was no diﬀerence in
Russia (p=0.15). In each case, the mean change from
baseline to LOCF endpoint MRS score was larger
in the ziprasidone group compared to the placebo
group. However, the diﬀerences between ziprasidone
and haloperidol were inconsistent between countries.
In India and Russia, the haloperidol group showed a
larger improvement than the ziprasidone group
(p=0.001 and p=0.007, respectively) ; whereas in
the USA, the ziprasidone group showed a non-
signiﬁcantly larger change from baseline compared to
the haloperidol group (p=0.14). Results were similarly
inconsistent when comparing the mean change
between countries (regardless of treatment group).
The mean change was signiﬁcantly greater in both
India and the USA than in Russia (p=0.004 and
p=0.03, respectively) but the mean change was not
signiﬁcantly diﬀerent when comparing the USA to
India (p=0.65). Finally, the mean change in MRS
scores across the treatment groups, controlling for
country, baseline MRS score and the countryrtreat-
treatment interaction, showed a signiﬁcant diﬀerence
between ziprasidone and placebo (p<0.001) favouring
ziprasidone and between haloperidol and placebo
(p<0.001), but no overall diﬀerence between ziprasi-
done and haloperidol (p=0.40).
Using the more stringent criteria for treatment re-
sponse (o50% decrease in MRS score from baseline to
LOCF endpoint), there was no signiﬁcant diﬀerence
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Fig. 1. Least squares (LS) mean change in Mania Rating Scale (MRS) score at week 3 following treatment with
ziprasidone or haloperidol by country. * p<0.005, ** p<0.0001.
Table 3. Relationships between therapeutic eﬀect and dose
at week 3
India Russia USA
Relationship between MRS change and mean modal dose, R2
(p value)
Ziprasidone 0.0001 (0.93) 0.001 (0.82) 0.013 (0.44)
Haloperidol 0.001 (0.78) 0.003 (0.70) 0.001 (0.81)
Relationship between MRS change and last dose of active
drug, R2 (p value)
Ziprasidone 0.0001 (0.94) 0.003 (0.73) 0.028 (0.35)
Haloperidol 0.04 (0.15) 0.012 (0.44) 0.002 (0.43)
MRS, Mania Rating Scale.
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between countries in the proportion of severely ill
subjects (baseline MRS scoreso30, p=0.07). However,
US subjects responded with the lowest frequency
overall (8/116, 6.9%) compared to Russia (23/139,
16.5%) and India (60/179, 33.5%). Notably, almost ﬁve
times as many severely ill subjects in India responded,
compared to those in the USA; more than twice
as many as Russia. When comparing treatments for
the above-mentioned category of subjects, there was a
signiﬁcant diﬀerence between groups (p=0.002). In
the ziprasidone group, 17.0% (30/176) of the subjects
responded, compared to 32.9% (56/170) of the
haloperidol group and 5.7% (5/88) of the placebo
group. There was no interaction between country and
treatment (p=0.55).
Placebo response across countries
Several reports of diﬀerences in outcomes between
countries and in drug vs. placebo eﬀects across sites
and over time, underscore the importance of this issue
in relation to the precision of clinical trials (Sysko &
Walsh, 2007 ; Walsh et al. 2002 ; Watsky et al. 2009).
Placebo response has been observed increasingly in
trials of major depressive disorders (Walsh & Sysko,
2005 ; Walsh et al. 2002) and bipolar mania (Sysko &
Walsh, 2007). Intriguingly, a recent report identiﬁed a
positive correlation between year of publication and
placebo response rate, with placebo response increas-
ing over time (Sysko & Walsh, 2007). While the cause
remains unclear, this observation could be attributed
to a number of factors, such as trial design and dur-
ation, severity of illness and additional rescue medi-
cation (Sysko & Walsh, 2007). Publication bias, and
particularly the prioritization of positive trials for
publication submission, has been reported to be the
most likely reason for these ﬁndings (Vieta & Cruz,
2008).
In this study, a higher placebo response was
observed in the USA (Fig. 1). However, these ﬁndings
diﬀered from other reports where placebo response
was higher in subjects at non-US sites (Watsky et al.
2009). The conﬂicting views in the literature regarding
the potential impact of geography on precision in
international clinical trials (Watsky et al. 2009) prompts
a more in-depth investigation into the diﬀerences in
patient populations and outcomes.
Relationship between outcome variables
In order to determine if severity of illness was con-
sistently measured, MRS score at visit was correlated
with the investigator’s rating of severity (CGI-S) using
a multiple regression model both at the beginning of
the study and post-baseline. The model also included
main eﬀects for treatment, country and treat-
mentrcountry with baseline MRS score as a covariate.
Overall, although there was a signiﬁcant correlation
(p<0.001) for all comparisons, there was no clear trend
with respect to country or treatment. In the post-
baseline comparisons of MRS and CGI-S scores, while
within the USA and India the correlations were close
between treatment groups, in Russia the correlations
were highest in the placebo group and lowest in the
haloperidol group (0.82 vs. 0.41, respectively).
When this analysis was extended to compare the
MRS score to another diagnostic scale (CGI-S), there
was a signiﬁcant relationship between the two scores
(p<0.0001). There was a signiﬁcant eﬀect for treatment
(p<0.0001) and country (p=0.007), and no interaction
between country and treatment (p=0.96). The re-
lationship was signiﬁcantly diﬀerent between halo-
peridol and both placebo and ziprasidone (p<0.0001
for each), and ziprasidone and placebo (p=0.053).
Furthermore, there was not a signiﬁcant diﬀerence
between India and Russia (p=0.10), but there was a
signiﬁcant diﬀerence between India and the USA
(p=0.002), and Russia and the USA (p=0.05).
In order to determine if improvement was consist-
ently measured by the investigator at each site, MRS
change from baseline to visit was correlated with
the investigator’s rating of improvement (CGI-I) using
a multiple regression model. The model also included
main eﬀects for treatment, country and treatmentr
country with baseline MRS as a covariate. Overall,
there was a signiﬁcant relationship between MRS
change from baseline and CGI-I (p<0.0001). While
there was no interaction between country and
treatment (p=0.13), there was a signiﬁcant eﬀect for
treatment (p<0.0001) and country (p<0.0001). The
relationship was signiﬁcantly diﬀerent between halo-
peridol and both placebo and ziprasidone (p<0.0001
for each), but ziprasidone and placebo were not sig-
niﬁcantly diﬀerent (p=0.73). Furthermore, there was
no signiﬁcant diﬀerence between India and Russia
(p=0.09), but there was a signiﬁcant diﬀerence be-
tween India and the USA (p<0.0001), and Russia and
the USA (p<0.0001).
In all the above analyses, we observed an incon-
sistency between the global rating (CGI) and the MRS
based upon which country the rating was conducted
in and the treatment that the subject received.
Safety
The next step was to ascertain the diﬀerences in safety
measures by country, as measured by the reported
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AEs. Table 4 shows the pairwise comparisons between
the ziprasidone group and the other treatment groups
within each country. In all three countries, the placebo
group had the fewest AEs, although the pattern
for ziprasidone and haloperidol varied by country
(Table 4). In Indian subjects, compared to the ziprasi-
done group, both placebo and haloperidol groups
had a signiﬁcantly diﬀerent number of AEs (p=0.04
for both comparisons). Nearly twice as many AEs
were reported in the ziprasidone-treated subjects as
the placebo-treated subjects, while nearly 1.5 times
as many AEs were reported in the haloperidol group
as in the ziprasidone group. In Russia, the pattern was
slightly diﬀerent with similar numbers of AEs in
the ziprasidone and placebo groups. The ziprasidone
group had half as many AEs as the haloperidol group
(p=0.04). In contrast to India and Russia, USA subjects
treated with ziprasidone reported almost 2.5 times as
many AEs compared to those on placebo (p<0.001),
although there was no diﬀerence compared to the
haloperidol group (p=0.10, n.s.).
Discontinuation
Discontinuation rates for those on an active drug were
highest in India (ziprasidone 35.1%, haloperidol
15.9%), followed by the USA (ziprasidone 12.5%,
haloperidol 23.4%) and lowest in Russia (ziprasidone
19.6%, haloperidol 10.9%) (Table 5).More ziprasidone-
and placebo-treated subjects discontinued due to lack
of eﬃcacy in all three countries (p=0.0098). The halo-
peridol group had similar incidences of discontinu-
ation due to lack of eﬃcacy across all countries.
Comparing rates of discontinuation due to treatment-
related AEs, only the haloperidol group showed a
signiﬁcant diﬀerence between countries (p=0.0007).
When comparing the treatment groups within a
country, there was a signiﬁcant diﬀerence between the
treatments for discontinuation due to lack of eﬃcacy
in India (p<0.0001). In Russia, there was no diﬀerence
among the treatments and in the USA there was a
diﬀerence in the rate of discontinuation due to treat-
ment-related AEs (p=0.02)
The median time until discontinuation in ziprasi-
done-treated subjects was longer than the placebo
group in India (it was not estimable in the USA and
Russia because <50% of the patients discontinued).
However, the median time until discontinuation from
haloperidol was only 14 d in the USA, compared to
24 d in Russia (Table 6). Finally, in the ziprasidone and
placebo groups, there was no signiﬁcant diﬀerence in
time to discontinuation across countries (Fig. 2a, c) ;
however it was signiﬁcantly diﬀerent across countries
in the haloperidol groups (p<0.001) (Fig. 2b).
Table 4. Comparison of adverse events (AEs) per subject
by treatment group and country
India Russia USA
N
Ziprasidone 74 56 48
Haloperidol 69 55 47
Placebo 36 28 24
LS mean number of AEs (S.E.)
Ziprasidone 1.51 (0.21) 0.61 (0.24) 3.27 (0.26)
Haloperidol 2.12 (0.22) 1.31 (0.24) 2.66 (0.26)
Placebo 0.78 (0.30) 0.46 (0.34) 1.38 (0.36)
LS mean number of AEs diﬀerence
Ziprasidone
Haloperidol x0.60a x0.70a 0.61
Placebo 0.74a 0.14 1.90b
LS, Least squares.
a p<0.05.
b p<0.001.
Table 5. Total discontinuations and discontinuations due to
adverse events (AEs) by country and treatment
India Russia USA
N
Ziprasidone 74 56 48
Haloperidol 69 55 47
Placebo 36 28 24
Total discontinuations, n (%)
Ziprasidone 26 (35.1) 11 (19.6) 6 (12.5)
Haloperidol 11 (15.9) 6 (10.9) 11 (23.4)
Placebo 21 (58.3) 7 (25.0) 5 (20.8)
p valuea <0.0001 0.2318 0.1876
Discontinuations due to AEs related to study drug, n (%)
Ziprasidone 3 (4.1) 1 (1.8) 3 (6.3)
Haloperidol 3 (4.3) 2 (3.6) 8 (17.0)
Placebo 1 (2.8) 0 0
p valuea 0.9053 0.6151 0.0237
Discontinuations due to lack of eﬃcacy, n (%)
Ziprasidone 23 (31.1) 10 (17.9) 3 (6.3)
Haloperidol 8 (11.6) 4 (7.3) 3 (6.4)
Placebo 20 (55.6) 7 (25.0) 5 (20.8)
p valuea <0.0001 0.0916 0.1783
a The p values represent a test between all three treatment
groups.
Cultural factors in an acute mania clinical trial 1023
Discussion
As more clinical trials are conducted at multiple sites
globally, it is necessary to identify potential sources
of variability in patient groups across countries that
may impact trial outcomes. In these post-hoc analyses,
we systematically compared baseline characteristics of
patients with bipolar mania, the treatment outcome
variables and safety data between countries (USA,
Russia, India) and treatment groups (ziprasidone,
haloperidol, placebo). Some of our analyses revealed
unexpected diﬀerences between countries and here we
discuss the source and likely impact of these diﬀer-
ences. Awareness of these distinctions can instruct a
smarter design of global psychiatric trials in the future.
Geographical diﬀerences in baseline characteristics
Nearly all baseline characteristics diﬀered in the
patient population, with the greatest diﬀerence be-
tween US and Indian subjects, and the Russian group
closely aligned with the US pool. Access to quality,
early psychiatric diagnosis and intervention in the
USA may be why US subjects were younger and had
tried more psychotropic medications for treatment
options. Indeed the high percentage of Indian subjects
with psychotic manic episodes suggests that patients
may be prioritized for clinical intervention based
on disease severity by their physicians. This was also
the case in a risperidone placebo-controlled study
(Khanna et al. 2005). It is possible that the higher
number of discontinuations in Indian subjects across
all treatment groups may be because the subjects were
more severely ill. Identifying the reasons for diﬀer-
ences in discontinuation rates is beyond the scope of
the present analyses. One explanation for the higher
discontinuation rates for haloperidol in the USA could
be that these subjects had lower tolerance to the drug.
Dosage disparities across countries
Our analyses conﬁrmed the disparity in dosing be-
tween countries. The drug dosage did not appear to
have been adjusted for weight, so subjects in India
who weighed the least received the highest doses.
Furthermore, the doses of haloperidol and ziprasidone
were not equivalent, since a dose of 2 mg/d haloper-
idol is equivalent to 60 mg/d ziprasidone (Vieta &
Cruz, 2008; Woods, 2003). This led to subjects in India
and Russia receiving doses of haloperidol higher than
that associated with optimal eﬃciency and tolerability,
and all subjects receiving doses of ziprasidone lower
than that associated with maximum eﬃcacy (Vieta &
Cruz, 2008 ; Woods, 2003). In the Khanna et al. (2005)
study conducted in India, risperidone was also dosed
much higher than usual. This may be because in some
cultures, similar to India, eﬃcacy is prioritized over
safety and in these countries trial patients tend to be
more severely aﬀected, whereas in the USA safety is
prioritized over eﬃcacy.
The lack of consistency in dosage between countries
appears to be driving a diﬀerence in outcomes.
However, the diﬀerential response may also be attrib-
uted to the severity of mania at baseline, where a
greater response is observed with increasing baseline
severity of mania. There is also growing acceptance in
the medical community that age, sex and BMI can all
impact basal metabolic systems, such as renal clear-
ance, and thereby impact clinical pharmacodynamics
(Han et al. 2007 ; Woods, 2003). These factors may
contribute to the diﬀerence in response proﬁles
amongst subjects in India compared to those in Russia
and the USA.
Furthermore, even though subjects in India received
higher mean doses of ziprasidone, they tended to stay
on the drug longer than subjects in Russia or the USA.
Overall it is not clear whether the high dosing was
Table 6. Time to discontinuation by country and treatment
India Russia USA p valuea
Ziprasidone 22 (22–23) n.e. (24xn.e.) n.e. (n.e.xn.e.) 0.024
Haloperidol n.e. (n.e.xn.e.) 24 (24xn.e.) 14 (9xn.e.) <0.0001
Placebo 16.5 (11–20) n.e. (n.e.xn.e.) n.e. (14xn.e.) 0.0094
Values given are median in days (95% CI).
CI, conﬁdence interval around median ; n.e., not estimable (e.g. not enough patients
discontinued to estimate the parameter of interest, median or upper limit of the
median).
a p value is derived from the comparison of time to discontinuation within treatment
groups across countries.
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necessary because the disease severity was higher,
because the therapeutic threshold in the Indian sub-
jects was higher or whether potentially unequal
investigator training led to diﬀerent prescribing prac-
tices. In any circumstance, further investigation is
warranted to understand these clinical and perhaps
cultural factors.
Geographical diﬀerences in placebo response
Subjects in diﬀerent countries may also respond dif-
ferently to participating in a clinical trial, as evidenced
by the disproportionately high placebo response
observed in the USA. Our results further substantiate
recent reports of diﬀerences in outcomes between
countries and variability in drug–placebo diﬀerences
across sites and over time (Sysko & Walsh, 2007 ; Vieta
& Cruz, 2008 ; Walsh & Sysko, 2005 ; Walsh et al. 2002 ;
Watsky et al. 2009).
Conversely, our results diﬀered from the observa-
tions from a phase 2a clinical trial in schizophrenia
that used a response criterion of o30% change in
PANSS from baseline and found a signiﬁcant active
control/placebo diﬀerence (p<0.1) in the USA, but not
outside the USA (Watsky et al. 2009). A higher re-
sponse criterion of o50% on the MRS or Young MRS
(YMRS) or a score of 1 or 2 on the CGI-I scale was
employed in the review of placebo response in bipolar
mania (Sysko &Walsh, 2007). This may account for the
diﬀerent ﬁndings in the schizophrenia study that de-
ﬁned response as ao30% change in PANSS, although
it could be related to the nature of the illness as well
(Watsky et al. 2009). These conﬂicting views in the
literature, along with the potential impact of geogra-
phy on precision in clinical trials remain debatable.
Lower severity, a well-known factor that increases
placebo response (Vieta & Carne, 2005), might have
played a role in the higher placebo response of US
subjects. Furthermore, in the USA, the treatment
of psychiatric illness is well established and the role
of clinical trials appears to be well comprehended
across potential subjects. This awareness might
actually favour the inclusion of subjects with lower
severity and greater insight into clinical trials, in-
directly fostering placebo response. Such cultural
considerations could have an impact on the recruit-
ment and outcomes of clinical trials in Russia and
India (Platonov, 2003 ; Raja et al. 2010 ; Shah et al. 2010).
Hence, to understand the diﬀerence in placebo re-
sponse, further research is necessary to examine the
relative contribution of the cultural diﬀerences across
subjects and inherent methodological factors in the
trial design (Sysko &Walsh, 2007 ; Vieta & Cruz, 2008).
Implications for global psychiatric clinical trials
With the continuing move towards the globalization
of clinical trials, the diﬀerence between subject
groups that we report here may have considerable
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Fig. 2. Kaplan–Meier curves for discontinuations over time
by country and treatment.
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implications for the design of clinical trials. When de-
signing multinational trials it may be beneﬁcial to
provide a smarter protocol that considers guidelines
that directly tackle these diﬀerences at the outset, rather
than discovering them after the trial completion.
One option would be to create study protocols that
assess diﬀerences in patient baseline characteristics,
such as severity of disease, duration of illness, weight/
BMI and treatment history prior to the ending of the
trial. However, this approach is problematic as most
psychiatric trials are relatively short and do not allow
for quick correction of the protocol to compensate
for diﬀerences seen in patient populations across
countries. Alternatively, a consensus approach prior to
the start of the trial to monitor patient recruitment is a
possibility where investigators from all sites make a
judgement on whether or not to include patients in the
trial. This latter strategy could prevent potential drift
of a single trial site and maintain uniformity in the
trial.
Given our ﬁndings of diﬀerences in dosing
approaches between countries, better training and a
clearly deﬁned dosing algorithm during the trial
can ensure that patients receive comparable doses.
Furthermore, this will also take into consideration
any apprehensions that investigators have regarding
newer drugs. Last, documenting and understanding
the factors inﬂuencing the diagnosis, severity of
the disease and the treatment approach in diﬀerent
countries should be an important consideration in
global clinical psychiatric trials.
Conclusions
Within each treatment group we found signiﬁcantly
diﬀerent baseline characteristics, treatment response
(including placebo response) and discontinuation by
country, indicating a need for further research to de-
termine whether this is the result of cultural diﬀer-
ences, baseline disease severity or diﬀering healthcare
practices among these countries. These diﬀerences
need to be fully examined and explained in order
to have international and intercontinental clinical
trials designed to ensure globally applicable results.
Furthermore, in the future it may be necessary to
analyse clinical data on a country-by-country basis to
account for any geographical diﬀerences.
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